Huang Dan, Liu Jian, Zong Rui-Kai, Wan Lei
Anhui University of Traditional Chinese Medicine Hefei 230038, China.
Department of Rheumatology,First Affiliated Hospital, Anhui University of Traditional Chinese Medicine Hefei 230031, China.
Zhongguo Zhong Yao Za Zhi. 2020 Jan;45(2):451-456. doi: 10.19540/j.cnki.cjcmm.20190619.501.
To investigate the efficacy of Huangqin Qingre Chubi Capsules(HQC) in patients with ankylosing spondylitis(AS) and its effect on oxidative stress, and to explore its possible mechanism. Fifty-eight cases of AS patients were randomly divided into HQC group and salazosulfapyridine(SASP) group. Another 30 healthy people were employed as a control group. Superoxide dismutase(SOD), total antioxidant capacity(TAOC), malondialdehyde(MDA), lipid peroxidatio(LPO), interleukin-1β(IL-1β), IL-10, IL-4, and tumor necrosis factor-α(TNF-α) were detected by ELISA. The mRNA expression levels of AMP-activated protein kinase(AMPK-α), forkhead box O3a(FOXO3a), manganese superoxide dismutase(MnSOD), and peroxisome proliferator-activated receptor gamma(PPARγ) were detected by Real-time fluorescence quantitative polymerase chain reaction(RT-qPCR). The protein expression levels of AMPK-α, FOXO3a, p-FOXO3a, MnSOD, and PPARγ were detected by Western blot. A questionnaire was used to evaluate the disease activity score and observe the clinical efficacy of HQC in AS patients. The levels of MDA, LPO, TNF-α, and IL-1β were significantly increased in the peripheral blood of AS patients, and SOD, TAOC, IL-4, IL-10 levels were significantly decreased. After HQC treatment, scores of disease active indexes were all decreased, and its clinical efficacy was significantly higher than that in SASP group. After HQC treatment, TAOC, SOD, IL-4, IL-10 were increased and MDA, LPO, TNF-α, IL-1β were decreased; mRNA levels of AMPK-α, FOXO3a, MnSOD, PPARγ and protein levels of AMPK-α, FOXO3a, p-FOXO3a, MnSOD, PPARγ were increased(P<0.01 or P<0.05). HQC can effectively improve the clinical symptoms and oxidative stress of AS patients, and its mechanism may be related to activating PPARγ and up-regulating AMPK/FOXO3a signal pathway.
探讨黄芩清热除痹胶囊(HQC)治疗强直性脊柱炎(AS)患者的疗效及其对氧化应激的影响,并探讨其可能的作用机制。将58例AS患者随机分为HQC组和柳氮磺胺吡啶(SASP)组。另选取30例健康人作为对照组。采用酶联免疫吸附测定(ELISA)法检测超氧化物歧化酶(SOD)、总抗氧化能力(TAOC)、丙二醛(MDA)、脂质过氧化(LPO)、白细胞介素-1β(IL-1β)、IL-10、IL-4和肿瘤坏死因子-α(TNF-α)。采用实时荧光定量聚合酶链反应(RT-qPCR)法检测腺苷酸活化蛋白激酶(AMPK-α)、叉头框蛋白O3a(FOXO3a)、锰超氧化物歧化酶(MnSOD)和过氧化物酶体增殖物激活受体γ(PPARγ)的mRNA表达水平。采用蛋白质免疫印迹法检测AMPK-α、FOXO3a、磷酸化FOXO3a(p-FOXO3a)、MnSOD和PPARγ的蛋白表达水平。采用问卷调查评估疾病活动评分,观察HQC对AS患者的临床疗效。AS患者外周血中MDA、LPO、TNF-α和IL-1β水平显著升高,SOD、TAOC、IL-4、IL-10水平显著降低。HQC治疗后,疾病活动指数评分均降低,其临床疗效显著高于SASP组。HQC治疗后,TAOC、SOD、IL-4、IL-10升高,MDA、LPO、TNF-α、IL-1β降低;AMPK-α、FOXO3a、MnSOD、PPARγ的mRNA水平及AMPK-α、FOXO3a、p-FOXO3a、MnSOD、PPARγ的蛋白水平升高(P<0.01或P<0.05)。HQC可有效改善AS患者的临床症状和氧化应激,其机制可能与激活PPARγ及上调AMPK/FOXO3a信号通路有关。